Current status and future trends of the global burden of MASLD

Trends in Endocrinology and Metabolism, Год журнала: 2024, Номер 35(8), С. 697 - 707

Опубликована: Фев. 29, 2024

Язык: Английский

---

The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: an international multidisciplinary expert consensus

Metabolism, Год журнала: 2024, Номер 161, С. 156028 - 156028

Опубликована: Сен. 11, 2024

Язык: Английский

---

Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review

Cardiovascular Diabetology, Год журнала: 2024, Номер 23(1)

Опубликована: Сен. 28, 2024

Язык: Английский

---

Liver diseases: epidemiology, causes, trends and predictions

Signal Transduction and Targeted Therapy, Год журнала: 2025, Номер 10(1)

Опубликована: Фев. 4, 2025

Abstract As a highly complex organ with digestive, endocrine, and immune-regulatory functions, the liver is pivotal in maintaining physiological homeostasis through its roles metabolism, detoxification, immune response. Various factors including viruses, alcohol, metabolites, toxins, other pathogenic agents can compromise function, leading to acute or chronic injury that may progress end-stage diseases. While sharing common features, diseases exhibit distinct pathophysiological, clinical, therapeutic profiles. Currently, contribute approximately 2 million deaths globally each year, imposing significant economic social burdens worldwide. However, there no cure for many kinds of diseases, partly due lack thorough understanding development these Therefore, this review provides comprehensive examination epidemiology characteristics covering spectrum from conditions manifestations. We also highlight multifaceted mechanisms underlying initiation progression spanning molecular cellular levels networks. Additionally, offers updates on innovative diagnostic techniques, current treatments, potential targets presently under clinical evaluation. Recent advances pathogenesis hold critical implications translational value novel strategies.

Язык: Английский

---

The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease

Hepatology International, Год журнала: 2025, Номер unknown

Опубликована: Фев. 27, 2025

Язык: Английский

---

Novel bioactive peptides alleviate Western diet-induced MAFLD in C57BL/6J mice by inhibiting NLRP3 inflammasome activation and pyroptosis via TLR4/NF-κB and Keap1/Nrf2/HO-1 signaling pathways

International Immunopharmacology, Год журнала: 2025, Номер 148, С. 114177 - 114177

Опубликована: Янв. 27, 2025

Metabolic-associated fatty liver disease (MAFLD) has emerged as a leading chronic disease. This condition is characterized by an abnormal accumulation of fat within and can progress from simple steatosis to more severe stages involving inflammation oxidative stress. In this study, we investigated the potential therapeutic effects underlying mechanism novel bioactive peptides (EWYF EWFY) on Western diet-induced MAFLD in C57BL/6J mice. Mice fed normal chow diet (ND group) (WD treatment groups) for 8 weeks. Treatment groups received EWYF EWFY low (10 mg/kg/day) high (50 doses were divided into four groups: EWYF10, EWYF50, EWFY10, EWFY50. body weight gain increased along with visceral adiposity, which markedly reversed dose-dependent manner. Additionally, significantly reduced hepatic steatosis, injury proinflammatory response. glucose tolerance insulin resistance, whereas improved sensitivity. Persistent intake triggered stress, alleviated via inhibiting NOD-like receptor protein 3 (NLRP3) inflammasome activation mitigated pyroptosis modulating TLR4/NF-κB Keap1/Nrf2/HO-1 signaling pathways. Furthermore, molecular docking studies suggest that act fructokinase antagonists TLR4 inhibitors, potentially alleviates MAFLD. Collectively, these findings highlight promising candidates due their potent antioxidant anti-inflammatory properties specific inhibition.

Язык: Английский

---

Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective

Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown

Опубликована: Фев. 18, 2025

ABSTRACT Background The continuum of metabolic syndrome encompasses a spectrum dysfunctions impacting obesity‐linked insulin resistance, glucose homeostasis, lipid metabolism and pro‐inflammatory immune responses. global prevalence diseases, including diabetes, chronic liver disease, cardiometabolic disease kidney has surged in recent decades, contributing significantly to population mortality. Metabolic dysfunction‐associated steatotic (MASLD), formerly known as non‐alcoholic fatty is leading cause worldwide. MASLD poses significant health challenge with its rising prevalence, placing substantial burden on healthcare systems, impacts patient well‐being incurs economic costs. Addressing requires comprehensive understanding interconnected factors, implications. Lack awareness, imprecise non‐invasive diagnostic methods ineffective preventive interventions are core components the MASLD‐related problem. Aim aim this article was summarise from payer's perspective. Methods We carried out review MASLD. These topics led discussions insights by an expert panel during 7th Continuum Roundtable meeting, which took place November 2023. This meeting focused burden, patient‐reported outcomes economics, payor societal perspectives, aimed identify opportunities for improving care, optimise resource allocation mitigate overall impact individuals society related During roundtable, emphasis emerged need greater awareness strategic deployment diagnostic, therapeutic preventative measures address effectively. Conclusion high growing. Prioritising prevention dysregulation timely can yield holistic strategy combat MASLD, progression potentially lower Trial Registration: NCT06309992

Язык: Английский

---

Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota

Metabolites, Год журнала: 2022, Номер 12(7), С. 647 - 647

Опубликована: Июль 14, 2022

Obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD) are characterized by the concepts of lipo- glucotoxicity. NAFLD is accumulation different lipidic species within hepatocytes. Bile acids (BA), derived from cholesterol, conjugated stored in gallbladder, help absorption/processing lipids, modulate host inflammatory responses gut microbiota (GM) composition. The latter new "actor" that links GI tract pathogenesis. In fact, discovery mechanistic characterization hepatic intestinal farnesoid X receptor (FXR) shed light on gut-liver axis. We conducted a search main medical databases for original articles, reviews, meta-analyses randomized clinical trials, case series using following keywords, their acronyms, associations: receptor, bile metabolism, microbiota, dysbiosis, steatosis. Findings synthesis, conjugation processes BAs, action FXR, change understanding physiopathology. detail, BAs act as ligands to several FXRs with GM modulation. On other hand, pool modulated GM, thus, regulating functioning frame fat deposition fibrosis development. conclusion, passed role simple lipid absorption metabolism agents messengers between liver, GM.

Язык: Английский

---

MAFLD as part of systemic metabolic dysregulation

Hepatology International, Год журнала: 2024, Номер 18(S2), С. 834 - 847

Опубликована: Апрель 9, 2024

Язык: Английский

---

From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function

Medical Science Monitor, Год журнала: 2024, Номер 30

Опубликована: Янв. 16, 2024

Metabolic dysfunction-associated fatty liver disease or metabolic steatotic (MAFLD/MASLD), is a common chronic condition affecting substantial global population. Beyond its primary impact on function, MAFLD/MASLD associated with myriad of extrahepatic manifestations, including cognitive impairment. The scope impairment within the realm matter escalating concern. Positioned as an intermediate stage between normal aging process and onset dementia, manifests challenge this condition. Insights from studies underscore presence compromised executive function decline in capabilities among individuals identified being at risk progressing to fibrosis. Importantly, transcends mere association factors, delving deep into intricate pathophysiology characterizing MAFLD/MASLD. multifaceted nature context underlined by spectrum prominently featuring insulin resistance, lipotoxicity, systemic inflammation pivotal contributors. These factors interplay landscape MAFLD/MASLD, fostering nuanced understanding links hepatic health function. By synthesizing available evidence, exploring potential mechanisms, assessing clinical implications, overarching aim review contribute more complete

Язык: Английский

---